{"filing":{"accession_number":"0001601830-26-000112","cik":"0001601830","ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-15","primary_document":"rxrx-20260915.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000112/rxrx-20260915.htm"},"events":[{"id":33916,"run_id":31221,"accession_number":"0001601830-26-000112","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Recursion entered into two material definitive agreements with Tempus AI on September 15, 2026: (1) an Amendment extending and materially modifying the existing Master Agreement, reducing annual license fees from $42M to $14M and eliminating Recursion's termination-for-convenience right, and (2) a new TxFM License Agreement granting Tempus a non-exclusive license to Recursion's proprietary RNA sequencing model for $12M in license fees plus data access. These are material commercial arrangements involving significant financial consideration and strategic intellectual property licensing that would affect a reasonable investor's assessment of the company's partnerships and revenue streams.","company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37511,"accession_number":"0001601830-26-000112","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Recursion entered into two material definitive agreements with Tempus AI on September 15, 2026: (1) an Amendment extending and materially modifying the existing Master Agreement, reducing annual license fees from $42M to $14M and eliminating Recursion's termination-for-convenience right, and (2) a new TxFM License Agreement granting Tempus a non-exclusive license to Recursion's proprietary RNA sequencing model for $12M in license fees plus data access. These are material commercial arrangements involving significant financial consideration and strategic intellectual property licensing that would affect a reasonable investor's assessment of the company's partnerships and revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T13:07:38.354561+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37511,"accession_number":"0001601830-26-000112","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Recursion entered into two material definitive agreements with Tempus AI on September 15, 2026: (1) an Amendment extending and materially modifying the existing Master Agreement, reducing annual license fees from $42M to $14M and eliminating Recursion's termination-for-convenience right, and (2) a new TxFM License Agreement granting Tempus a non-exclusive license to Recursion's proprietary RNA sequencing model for $12M in license fees plus data access. These are material commercial arrangements involving significant financial consideration and strategic intellectual property licensing that would affect a reasonable investor's assessment of the company's partnerships and revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T13:07:38.354561+00:00","company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","filing_date":"2026-09-21"}]}